[1]鞠永健.放射治疗中肿瘤控制概率的影响因素[J].国际放射医学核医学杂志,2002,26(4):183-186.
 JU Yong-jian.The influential factors of tumor control probability in radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):183-186.
点击复制

放射治疗中肿瘤控制概率的影响因素(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第4期
页码:
183-186
栏目:
放射医学
出版日期:
1900-01-01

文章信息/Info

Title:
The influential factors of tumor control probability in radiotherapy
作者:
鞠永健
300192 天津, 中国医学科学院中国协和医科大学放射医学研究所
Author(s):
JU Yong-jian
Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
关键词:
肿瘤控制概率放射治疗克隆源性细胞
Keywords:
tumor control probabilityradiotherapyclonogencell
分类号:
R144.1
摘要:
可靠的肿瘤控制概率计算模型是对放射治疗方案进行准确评估的基础。所以,对肿瘤控制概率模型中所涉及的参数及对这些参数取值有影响的因素进行总结有利于提出更完善的计算模型。
Abstract:
The reliabie tumor control probability (TCP) model is fundamental to evaluate the effect of the protocol accurately in radiotherapy. In order to obtain the optimum TCP model, the parameters included in the model and the factors which can affect these parameters have been summarized.

参考文献/References:

[1] Skladowski K, Tarnawski R, Maciejewski B, et al. Clinical radiobiology of glottic T1 squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 1999, 43:101-109.
[2] Buffa FM and Nahum AE. Monte Carlo dose calculations and radiobiological modelling:analysis of the effect of the statistical noise of the dose distribution on the probability of tumour control[J]. Phy Med Biol, 2000, 45: 3009-3023.
[3] Willner J, Baier K, Pfreundner L, et al. Tumor volume and local control in primary radiotherapy of nasopharyngeal carcinoma[J]. Acta Oncolica, 1999, 38:1025-1030.
[4] Buffa FM, Fenwick JD and Nahum AE. An analysis of relationship between radiosensitivity and volume effects in tumor control probability modeling[J]. Med Phys, 2000, 27:1258-1265.
[5] Bentzen SM and Tucker SL. Quantifying the position and steepness of radiation dose-response curves[J]. Int J Radiat Biol, 1997, 71:531-542.
[6] Britten RA, Evans AJ, Allalunis-Turner MJ, et al. Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumour radioresponsiveness[J]. Racliother and Oncol, 1996, 39:145-153.
[7] Laasonen A, Pyrhonen S, Kouri, et al. The effect of fractionated irradiation on cell kinetics[J]. Acta Oncologica, 1991, 30:51-56.
[8] Urano M, Nishimura Y, Kuroda M, et al. Are hypoxic cells critical for the outcome of fractionated radiotherapy in a slow-growing mouse tumor[J]. Radiother and Oncol, 1998, 48:221-228.
[9] Gatti RA. The inherited basis of human radiosensjtivity[J]. Acta Oncolgica, 2001, 40:702-711.
[10] Eastham AM, Atkinson J and West CML. Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines[J]. Int J Radiat Biol, 2001, 77:295-302.
[11] Sikpi MO and Wang Y. Ionizing radiation enhances doublestrand-break repair in rapamycin-treated ataxia telangiectasia lymphoblasts[J]. Int J Radiat Biol, 2000, 76:177-187.
[12] Wilson GD. A new look at proliferation[J]. Acta Oncologica, 2001, 40:989-994.
[13] Jones B and Dale RG. Mathematical models of tumour and normal tissue response[J]. Acta Oncologica, 1999, 38:883-893.
[14] Budach W, Gioioso D, Taghian A, et al. Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro[J]. Int J Radiat Oncol Biol Phys, 1997, 39:743-750.
[15] Fowler JF. Biological factors influencing optimum fractionat ion in radiation therapy[J]. Acta Oncologica, 2001, 40:712-717.
[16] Baumann M, Petersen C, Schulz P, et al. Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionat ed irradiation[J]. Radiother and Oncol, 1999, 50:107-111.
[17] Baumann M, Hertz C, Baisch H, et al. Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice[J]. Radiother and Oncol, 1994, 32:137-143.
[18] Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous carcinoma during fractionated radiotherapy correlates with reoxygenation[J]. Int J Radiat Oncol Biol Phys, 2001, 51:483-493.
[19] Roberts SA and Hendry JH. The delay before onset of accelerated tumour cell repopulation during radiotherapy:a direct maximum-likelihood analysis of a collection of worldwide tumour-control data[J]. Radiother and Oncol, 1993, 29:69-74.
[20] Thames HD, Ruifrok ACC, Milas L, et al. Accelerated repopulationduring fractionated irradiation of a murine ovarian carcinoma:downregulation of apoptosis as a possible mechanism[J]. Int J Radiat Oncol Biol Phys, 1996, 35:951-962.
[21] Beck-Bornholdt HP, Omniczynski M, Theis E, et al. Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation[J]. Acta Oncologica, 1991, 30:57-63.
[22] Roberts SA and Hendry JH. Time factors in larynx tumor radiotherapy:lag times and intertumor heterogeneity in clinical datasets from four centers[J]. Int J Radiat Oncol Biol Phys, 1999, 45:1247-1257.
[23] Sanchez-Nieto B, Nahum AE and Dearnaley DP. Individualization of dose prescription based on normal-tissue dosevolume and radiosensitivity data[J]. Int J Radiat Oncol Biol Phys, 2001, 49:487-499.

相似文献/References:

[1]姜炜.血管的辐射损伤[J].国际放射医学核医学杂志,2005,29(1):37.
 JIANG Wei.Radiation injury of blood vessels[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):37.
[2]袁志斌.89Sr及联合治疗转移性骨肿瘤的临床应用[J].国际放射医学核医学杂志,2005,29(2):53.
 YUAN Zhi-bin.The clinical application of strontium-89 concomitant use with other modalities in the treatment of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):53.
[3]盛晓芳,管一晖,赵军,等.PET-CT在脑胶质瘤放射治疗靶区确定中的应用[J].国际放射医学核医学杂志,2005,29(6):241.
 SHENG Xiao-fang,GUAN Yi-hui,ZHAO Jun,et al.Application of PET-CT in delineation of radiotherapy planning target volume for glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):241.
[4]郑爱青,于金明.对乏氧和射线应答的嵌合性基因启动子的研究进展[J].国际放射医学核医学杂志,2004,28(2):74.
 ZHENG Ai-qing,YU Jin-ming.Development of chimeric gene promoters responsive to hypoxia and ionizing radiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):74.
[5]张永权,巴特尔,刘文力.多发性脑转移瘤的立体定向伽玛刀治疗[J].国际放射医学核医学杂志,2004,28(2):94.
 Zhang Yong-quan,Bateer,Liu Wen-li.The treatment on multiple brain metastasis by stereotactic gamma knife[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):94.
[6]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
 CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):153.
[7]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
 LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):157.
[8]刘光伟,龚守良.siRNA与肿瘤放射治疗[J].国际放射医学核医学杂志,2004,28(4):169.
 LIU Guang-wei,GONG Shou-liang.siRNA and tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):169.
[9]刘强.放射性脑损伤研究现状[J].国际放射医学核医学杂志,2004,28(4):178.
 LIU Qiang.Present investigation of radiation brain injury[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):178.
[10]陆克义,李险峰.甲状腺疾病患者131I治疗后对他人的辐射危害评价[J].国际放射医学核医学杂志,2004,28(5):226.
 LU Ke-yi,LI Xian-feng.Evaluation of radiation exposure from patients with thyroid disease by 131I therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):226.

备注/Memo

备注/Memo:
收稿日期:2002-06-18。
基金项目:国家自然科学基金资助项目(39670228)
作者简介:鞠永健(1973-),男,江苏泰兴人,博士研究生,主要从事辐射剂量学及放射治疗中肿瘤控制概率模型的研究。
更新日期/Last Update: 1900-01-01